Cargando…
Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
CCAAT/enhancer binding protein β (C/EBPβ) is a basic leucine zipper (bZIP) family transcription factor, which is upregulated or overactivated in many cancers, resulting in a gene expression profile that drives oncogenesis. C/EBPβ dimerization regulates binding to DNA at the canonical TTGCGCAA motif...
Autores principales: | Darvishi, Emad, Ghamsari, Lila, Leong, Siok F., Ramirez, Ricardo, Koester, Mark, Gallagher, Erin, Yu, Miao, Mason, Jody M., Merutka, Gene, Kappel, Barry J., Rotolo, Jim A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630826/ https://www.ncbi.nlm.nih.gov/pubmed/36121385 http://dx.doi.org/10.1158/1535-7163.MCT-21-0962 |
Ejemplares similares
-
Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
por: Rossmueller, Gregor, et al.
Publicado: (2023) -
SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
por: Mazahreh, Rebecca, et al.
Publicado: (2023) -
A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer
por: Deng, Jiaojiao, et al.
Publicado: (2021) -
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
por: Okajima, Daisuke, et al.
Publicado: (2021) -
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
por: Murray, Brion W., et al.
Publicado: (2021)